Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (871-880 of 968) with videos related to

Pageof 97
Sort By:
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
Pageof 97

Showing results (871-880 of 968) with videos related to

Sort By:
Pageof 97
Blood Cancer Journal|February 18, 2025
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myelomaSaurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Leukemia|March 28, 2018
Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteriaEli Muchtar, Angela Dispenzieri, Nelson Leung, et al.
Blood Cancer Journal|August 1, 2018
Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaShaji K Kumar, Francis K Buadi, Betsy LaPlant, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 29, 2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group reportAntonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2020
Implications of MYC Rearrangements in Newly Diagnosed Multiple MyelomaNadine Abdallah, Linda B Baughn, S Vincent Rajkumar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2019
Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction TherapyBharat Nandakumar, Shaji K Kumar, Angela Dispenzieri, et al.
Pageof 97